A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care in the Treatment

Grants and Contracts Details

StatusActive
Effective start/end date6/30/203/21/23

Funding

  • Covance (foreign): $28,989.00